DK2367944T3 - PROMOTERS FOR RECOMBINANT VIRAL EXPRESSION - Google Patents
PROMOTERS FOR RECOMBINANT VIRAL EXPRESSION Download PDFInfo
- Publication number
- DK2367944T3 DK2367944T3 DK09764186.4T DK09764186T DK2367944T3 DK 2367944 T3 DK2367944 T3 DK 2367944T3 DK 09764186 T DK09764186 T DK 09764186T DK 2367944 T3 DK2367944 T3 DK 2367944T3
- Authority
- DK
- Denmark
- Prior art keywords
- promoter
- vector
- nucleic acid
- sequence
- mva
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/60—Vectors comprising a special translation-regulating system from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08020617 | 2008-11-27 | ||
| PCT/EP2009/008459 WO2010060632A1 (en) | 2008-11-27 | 2009-11-27 | Promoters for recombinant viral expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2367944T3 true DK2367944T3 (en) | 2019-04-15 |
Family
ID=40419479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09764186.4T DK2367944T3 (en) | 2008-11-27 | 2009-11-27 | PROMOTERS FOR RECOMBINANT VIRAL EXPRESSION |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8772023B2 (OSRAM) |
| EP (1) | EP2367944B1 (OSRAM) |
| JP (2) | JP2012509678A (OSRAM) |
| AU (1) | AU2009319336B2 (OSRAM) |
| CA (1) | CA2741724C (OSRAM) |
| DK (1) | DK2367944T3 (OSRAM) |
| NZ (1) | NZ592082A (OSRAM) |
| WO (1) | WO2010060632A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA024749B1 (ru) | 2008-11-21 | 2016-10-31 | Бавариан Нордик А/С | Экспрессионный вектор со сниженным уровнем внутримолекулярной рекомбинации, содержащий гомологичные или гетерологичные нуклеотидные последовательности |
| EP2788021B1 (en) | 2011-12-09 | 2017-01-18 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
| EP2864487B1 (en) | 2012-06-22 | 2018-12-05 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| IN2015DN03326A (OSRAM) | 2012-10-28 | 2015-10-09 | Bavarian Nordic As | |
| KR20160140075A (ko) | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
| CA2987159A1 (en) * | 2015-06-15 | 2016-12-22 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| HUE059343T2 (hu) | 2016-01-29 | 2022-11-28 | Bavarian Nordic As | Rekombináns, módosított Ankara Vaccinia vírus (MVA) és ló encephalitis vírus oltóanyag |
| US11052139B2 (en) | 2016-09-28 | 2021-07-06 | Bavarian Nordic A/S | Compositions and methods for enhancing the stability of transgenes in poxviruses |
| WO2018091680A1 (en) | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| JP7110203B2 (ja) | 2016-12-28 | 2022-08-01 | トランジェーヌ | 腫瘍溶解性ウイルスおよび治療用分子 |
| BR112019026126A2 (pt) | 2017-06-15 | 2020-06-30 | Janssen Vaccines & Prevention B.V. | vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos |
| WO2019020543A1 (en) | 2017-07-28 | 2019-01-31 | Transgene Sa | ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS |
| BR112020003669A2 (pt) | 2017-08-24 | 2020-09-01 | Bavarian Nordic A/S | terapia de combinação para tratamento do câncer com administração intravenosa de um mva recombinante e de um anticorpo |
| MX2020006471A (es) | 2017-12-19 | 2020-09-22 | Janssen Sciences Ireland Unlimited Co | Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv). |
| WO2020011754A1 (en) | 2018-07-09 | 2020-01-16 | Transgene | Chimeric vaccinia viruses |
| JP7555334B2 (ja) | 2018-10-05 | 2024-09-24 | バヴァリアン・ノルディック・アクティーゼルスカブ | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 |
| JP7625518B2 (ja) | 2018-11-20 | 2025-02-03 | バヴァリアン・ノルディック・アクティーゼルスカブ | ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法 |
| EP4061406A1 (en) | 2019-11-20 | 2022-09-28 | Bavarian Nordic A/S | Recombinant mva viruses for intratumoral and/or intravenous administration for treating cancer |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| WO2023118563A1 (en) | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Therapy for modulating immune response with recombinant mva encoding il-12 |
| EP4452305A1 (en) | 2021-12-23 | 2024-10-30 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| CN119630419A (zh) | 2022-06-29 | 2025-03-14 | 巴法里安诺迪克有限公司 | 重组修饰的saRNA(VRP)和痘苗病毒安卡拉(MVA)初免-加强方案 |
| TW202413636A (zh) | 2022-08-18 | 2024-04-01 | 法商傳斯堅公司 | 嵌合痘病毒 |
| WO2024149832A1 (en) | 2023-01-12 | 2024-07-18 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0568539A4 (en) * | 1990-11-06 | 1994-07-06 | Childrens Medical Center | Soluble mannose receptor peptides |
| US7314974B2 (en) * | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
| US7312202B2 (en) * | 2003-02-18 | 2007-12-25 | Board Of Regents, The University Of Texas System | Rationally designed and chemically synthesized promoter for genetic vaccine and gene therapy |
| DK1536015T3 (da) * | 2003-11-24 | 2008-02-18 | Bavarian Nordic As | Promotorer til ekspression i modificeret vacciniavirus Ankara |
| EP2864487B1 (en) * | 2012-06-22 | 2018-12-05 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
-
2009
- 2009-11-27 AU AU2009319336A patent/AU2009319336B2/en active Active
- 2009-11-27 CA CA2741724A patent/CA2741724C/en active Active
- 2009-11-27 DK DK09764186.4T patent/DK2367944T3/en active
- 2009-11-27 EP EP09764186.4A patent/EP2367944B1/en active Active
- 2009-11-27 JP JP2011537890A patent/JP2012509678A/ja active Pending
- 2009-11-27 NZ NZ592082A patent/NZ592082A/xx unknown
- 2009-11-27 WO PCT/EP2009/008459 patent/WO2010060632A1/en not_active Ceased
- 2009-11-27 US US13/131,586 patent/US8772023B2/en active Active
-
2014
- 2014-06-03 US US14/295,275 patent/US20140342403A1/en not_active Abandoned
-
2015
- 2015-11-26 JP JP2015230172A patent/JP6291467B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009319336B2 (en) | 2015-03-26 |
| US20120121617A1 (en) | 2012-05-17 |
| JP6291467B2 (ja) | 2018-03-14 |
| WO2010060632A1 (en) | 2010-06-03 |
| JP2016073297A (ja) | 2016-05-12 |
| CA2741724A1 (en) | 2010-06-03 |
| AU2009319336A1 (en) | 2010-06-03 |
| JP2012509678A (ja) | 2012-04-26 |
| US20140342403A1 (en) | 2014-11-20 |
| EP2367944B1 (en) | 2019-01-09 |
| US8772023B2 (en) | 2014-07-08 |
| CA2741724C (en) | 2016-10-04 |
| NZ592082A (en) | 2013-03-28 |
| EP2367944A1 (en) | 2011-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2367944T3 (en) | PROMOTERS FOR RECOMBINANT VIRAL EXPRESSION | |
| CA2751301C (en) | Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines | |
| EP2912183B1 (en) | Pr13.5 promoter for robust t-cell and antibody responses | |
| JP4421188B2 (ja) | 変性ワクシニアアンカラウイルス変異体 | |
| US20200325477A1 (en) | Compositions and Methods for Inducing an Enhanced Immune Response Using Poxvirus Vectors | |
| KR102259277B1 (ko) | 재조합 ｏｒｆ 바이러스 벡터 | |
| US11753652B2 (en) | Cassette encoding a FPV/brachyury fusion protein | |
| EP1567653B1 (en) | Recombinant poxvirus comprising at least two cowpox ati promoters | |
| US9163237B2 (en) | Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements | |
| WO2000073476A1 (en) | Vector for integration of heterologous sequences into poxviral genomes | |
| AU2017228587B2 (en) | Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines | |
| HK1254405B (en) | Promoters for enhancing expression in poxviruses |